MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2025-02-28
Last Posted Date
2025-04-29
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
26
Registration Number
NCT06851871
Locations
🇺🇸

Local Institution - 0001, Austin, Texas, United States

A Study to Prevent Infantile Spasms Relapse

Phase 2
Recruiting
Conditions
Infantile Spasms
Infantile Epileptic Spasms Syndrome
West Syndrome
Interventions
First Posted Date
2025-02-11
Last Posted Date
2025-05-08
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
40
Registration Number
NCT06819670
Locations
🇺🇸

UCLA, Los Angeles, California, United States

Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia

Phase 4
Not yet recruiting
Conditions
Ordinary Disorder Needed Planned Surgery and General Anesthesia
Interventions
First Posted Date
2024-12-19
Last Posted Date
2024-12-19
Lead Sponsor
Kim, Young Sung
Target Recruit Count
174
Registration Number
NCT06743243
Locations
🇰🇷

Korea University Medical Center, Guro Hospital, Seoul, Korea, Republic of

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

First Posted Date
2024-03-27
Last Posted Date
2024-03-27
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
36
Registration Number
NCT06332638
Locations
🇰🇷

Inje University Busan Paik Hospital, Busan, Korea, Republic of

Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients

Phase 1
Completed
Conditions
Breast Cancer
Filgrastim Adverse Reaction
Interventions
First Posted Date
2024-02-20
Last Posted Date
2024-12-13
Lead Sponsor
Noha Mansour
Target Recruit Count
58
Registration Number
NCT06265077
Locations
🇪🇬

Mansoura University, Mansoura, Province, Egypt

Famotidine and Antacids for Treatment of Dyspepsia

Phase 4
Recruiting
Conditions
Acid Reflux
Dyspepsia
GERD
Interventions
First Posted Date
2024-02-05
Last Posted Date
2025-05-01
Lead Sponsor
Stony Brook University
Target Recruit Count
80
Registration Number
NCT06241183
Locations
🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant

Phase 1
Recruiting
Conditions
Healthy Participants
Interventions
First Posted Date
2024-01-19
Last Posted Date
2025-03-14
Lead Sponsor
Incyte Corporation
Target Recruit Count
180
Registration Number
NCT06213818
Locations
🇦🇺

Nucleus Network Pty Ltd, Melbourne, Victoria, Australia

Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting

Not Applicable
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
First Posted Date
2024-01-18
Last Posted Date
2025-03-11
Lead Sponsor
Aswan University Hospital
Target Recruit Count
50
Registration Number
NCT06211088
Locations
🇪🇬

Zaher, Cairo, Egypt

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients with Metastatic Appendiceal Adenocarcinoma

Phase 1
Recruiting
Conditions
Metastatic Appendiceal Adenocarcinoma
Intraperitoneal Paclitaxel
Interventions
First Posted Date
2024-01-16
Last Posted Date
2025-01-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
39
Registration Number
NCT06207305
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2023-12-14
Last Posted Date
2024-07-01
Lead Sponsor
Celgene
Target Recruit Count
32
Registration Number
NCT06170723
Locations
🇺🇸

Local Institution - 0001, Tempe, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath